Clinical Research Alliance

Summary

Clinical Research Alliance is a medical facility located in New Hyde Park, New York. This center is recognized for care of Lung Cancer, Breast Cancer, Lymphoma, Non-Small Cell Lung Cancer, Chronic Lymphocytic Leukemia and other specialties. Clinical Research Alliance is involved with conducting 68 clinical trials across 123 conditions. There are 3 research doctors associated with this hospital, such as James T D'Olimpio, MD, Morton MD Coleman, doctor, and James D Olimpio.

Top PIs

Clinical Trials running at Clinical Research Alliance

Lung Cancer

Breast Cancer

Non-Small Cell Lung Cancer

Chronic Lymphocytic Leukemia

Cancer

Follicular Lymphoma

Lymphoma

Brain Tumor

Solid Tumors

MALT Lymphoma

Cancer Vaccine

for Lung Cancer

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Recruiting

2 awards

Phase 3

2 criteria

Divarasib + Pembrolizumab

for Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

Recruiting

2 awards

Phase 3

7 criteria

Trastuzumab Deruxtecan + Pembrolizumab

for Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Recruiting

2 awards

Phase 3

4 criteria